The American Journal of Medicine
Volume 121, Issue 6, Supplement , Pages S35-S41 , June 2008

Insulin Delivery Systems: Reducing Barriers to Insulin Therapy and Advancing Diabetes Mellitus Treatment

  • Stephen Brunton, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Stephen Brunton, MD, 7011 Summerhill Ridge Drive, Charlotte, North Carolina 28226.

References 

  1. Coates P, Ollerton R, Luzio S, et al. A glimpse of the natural history of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract. 1994;26:177–197
  2. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;29:977–986
  3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPD33). Lancet. 1998;352:837–853
  4. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643–2653
  5. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103–117
  6. Polonsky WH, Fisher L, Guzman S, et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 2005;28:2543–2545
  7. United Kingdom Prospective Diabetes Study Group (UKPDS). UKPDS 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 1995;310:83–88
  8. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers. Diabetes Care. 2005;28:2673–2679
  9. Mollema ED, Snoek FJ, Ader HJ, et al. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res. 2001;51:665–672
  10. Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg. 2003;68:341–344
  11. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes. 2002;26(suppl 3):S1–S7
  12. Haque M, Emerson SH, Dennison CR, et al. Barriers to initiating insulin therapy in patients with type 2 diabetes mellitus in public-sector primary health care centres in Cape Town. S Afr Med J. 2005;95:798–802
  13. Koerbel G, Korytkowski M. Insulin-therapy resistance: another form of insulin resistance in type 2 diabetes. Practical Diabetology. 2003;22:36–40
  14. Leslie CA, Satin-Rapaport W, Matheson RN, et al. Psychological insulin resistance: a missed diagnosis?. Diabetes Spectrum. 1994;7:52–57
  15. Tibaldi J. Initiating and intensifying insulin therapy in type 2 diabetes mellitus. Am J Med. 2008;121(suppl 6A):S20–S29
  16. Rolla A. Pharmacokinetic and pharmacodynamics advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety. Am J Med. 2008;121(suppl 6A):S9–S19
  17. Graff MR, McClanahan MA. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 1998;20:486–496
  18. Da Costa S. A comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educ. 2002;28:52–60
  19. American Diabetes Association. Insulin delivery. In: American Diabetes Association. Diabetes Forecast: 2007 Resource Guide [ADA Website] www.diabetes.org/diabetes-forecast/resource-guide.jspAccessed May 1, 2007
  20. Korytkowski M, Bell D, Jacobsen C, Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 2003;25:2836–2848
  21. Venekamp WJ, Kerr L, Dowsett SA, et al. Functionality and acceptability of a new electronic insulin injection pen with a memory feature. Curr Med Res Opin. 2006;22:315–325
  22. Asakura T. Comparison of the dosing accuracy of two insulin injection devices. J Drug Assess. 2005;8:201–208
  23. Clarke A, Dain MP. Dose accuracy of a reusable insulin pen using a cartridge system with an integrated plunger mechanism. Exp Opin Drug Deliv. 2006;3:677–683
  24. Egekvist H, Bjerring P, Arendt-Nielsen L. Pain and mechanical injury of human skin following needle insertions. Eur J Pain. 1999;3:41–49
  25. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004;27:894–903
  26. Korytkowski M, Niskanen L, Asakura T. FlexPen®: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 2005;27(suppl B):S89–S100
  27. Le Floch JP, Herbreteau C, Lange F, Perlemuter L. Biological material in needles and cartridges after insulin injection with a pen in diabetic patients. Diabetes Care. 1998;21:1502–1504
  28. Pellissier G, Migueres B, Tarantola A, et al. GERES group Risk of needlestick injuries by injection pens. J Hosp Infect. 2006;63:60–64
  29. Del Roio R, Damiani D. Insulin pump therapy in type 1 diabetes mellitus. J Pediatr. 2006;82:249–254
  30. Pickup J, Mattock M, Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised control trials. BMJ. 2002;324:705
  31. Weissberg-Benchell J, Antisdel-Lomaglio J, Sheshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care. 2003;6:1079–1087
  32. Doyle EA, Weinzimer SA, Steffen AT, et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004;27:1554–1558
  33. Usian MM, Burton DM, Chertow BS, Collins R. Accessibility of insulin pumps for blind and visually impaired people. Diabetes Technol Ther. 2004;6:621–634
  34. Saudek CD. Novel forms of insulin delivery. Endocrinol Metab Clin North Am. 1997;26:599–610
  35. Sulli N, Shashaj B. Continuous subcutaneous insulin infusion in children and adolescents with diabetes mellitus: decreased HbA1c with low risk of hypoglycemia. J Pediatr Endocrinol Metab. 2003;16:393–399
  36. DeVries JH, Snook FJ, Kostense PJ, et al. Dutch Insulin Pump Study Group A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care. 2002;25:2074–2080
  37. Guilhem I, Leguerrier AM, Lecordier F, et al. Technical risks with subcutaneous insulin infusion. Diabetes Metab. 2006;32:279–284
  38. Cefalu WT. Concept, strategies and feasibility of noninvasive insulin delivery. Diabetes Care. 2004;27:239–246
  39. Rosenstock J, Zinman B, Murphy LJ, et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized controlled trial. Ann Intern Med. 2005;143:549–558
  40. Skyler JS, Cefalu WT, Kourides IA, et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet. 2001;357:331–335
  41. Skyler JS, Weinstock RS, Raskin P, et al. Inhaled Insulin Phase III Type 1 Diabetes Study Group Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized comparative trial. Diabetes Care. 2005;28:1630–1635
  42. Ceglia L, Lau J, Pittas AG. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med. 2006;145:665–675
  43. Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes mellitus: a randomized controlled trial. Diabetes Care. 2001;24:1556–1559
  44. Cappelleri JC, Cefalu WT, Rosenstock J, et al. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther. 2002;24:552–564
  45. Laube B. Treating diabetes with aerosolized insulin. Chest. 2001;120:99–106
  46. Himmelmann A, Jendles J, Mellen A, et al. The impact of smoking on inhaled insulin. Diabetes Care. 2003;26:677–682
  47. Stoever JA, Palmer JP. Inhaled insulin and insulin antibodies: a new twist to an old debate. Diabetes Technol Ther. 2002;4:157–161
  48. Farr SJ, Rowe AM, Rubsamen R, Taylor G. Aerosol deposition in the human lung following administration from a microprocessor controlled pressurized metered dose inhaler. Thorax. 1995;50:639–644

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)00312-4

doi: 10.1016/j.amjmed.2008.03.025

The American Journal of Medicine
Volume 121, Issue 6, Supplement , Pages S35-S41 , June 2008

Article Tools

* Image Usage & Resolution